{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:19:30Z","timestamp":1789507170632,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1517-z","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T12:42:38Z","timestamp":1517316158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group"],"prefix":"10.1186","volume":"20","author":[{"name":"EUSTAR co-workers on behalf of the DeSScipher project research group within the EUSTAR network","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Adler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00f6rte","family":"Huscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Siegert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Czirj\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"DelGaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Frerix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Mueller-Ladner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo-Helmut","family":"Tarner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich A.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Villiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Riemekasten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,30]]},"reference":[{"issue":"10","key":"1517_CR1","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1002\/art.30467","volume":"63","author":"D Khanna","year":"2011","unstructured":"Khanna D, Tseng CH, Farmani N, Steen V, Furst DE, Clements PJ, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum. 2011;63(10):3078\u201385.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1517_CR2","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","volume":"66","author":"VD Steen","year":"2007","unstructured":"Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66(7):940\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1517_CR3","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1136\/ard.2008.096677","volume":"68","author":"O Kowal-Bielecka","year":"2009","unstructured":"Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68(5):620\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1517_CR4","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","volume":"176","author":"DP Tashkin","year":"2007","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2\u00a0years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176(10):1026\u201334.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"1517_CR5","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/rheumatology\/kel244","volume":"46","author":"SI Nihtyanova","year":"2007","unstructured":"Nihtyanova SI, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis\u2009\u2212\u2009-a retrospective analysis. Rheumatology (Oxford). 2007;46(3):442\u20135.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"1517_CR6","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s10067-010-1498-z","volume":"29","author":"A Koutroumpas","year":"2010","unstructured":"Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol. 2010;29(10):1167\u20138.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"1517_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00408-013-9499-8","volume":"191","author":"ST Panopoulos","year":"2013","unstructured":"Panopoulos ST, Bournia VK, Trakada G, Giavri I, Kostopoulos C, Sfikakis PP. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study. Lung. 2013;191(5):483\u20139.","journal-title":"Lung"},{"issue":"9","key":"1517_CR8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708\u201319.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"1517_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1164\/ajrccm\/144.2.291","volume":"144","author":"G Raghu","year":"1991","unstructured":"Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis. 1991;144(2):291\u20136.","journal-title":"Am Rev Respir Dis"},{"key":"1517_CR10","doi-asserted-by":"crossref","unstructured":"Poormoghim H, Rezaei N, Sheidaie Z, Almasi AR, Moradi-Lakeh M, Almasi S, et al. Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement-a retrospective study. Rheumatol Int. 2014;34(12):1691-9.","DOI":"10.1007\/s00296-014-3026-y"},{"issue":"2","key":"1517_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10067-005-1157-y","volume":"25","author":"O Nadashkevich","year":"2006","unstructured":"Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2006;25(2):205\u201312.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"1517_CR12","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54(12):3962\u201370.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1517_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.semarthrit.2012.01.003","volume":"42","author":"KM Walker","year":"2012","unstructured":"Walker KM, Pope J, participating members of the Scleroderma Clinical Trials C, Canadian Scleroderma Research G. Treatment of systemic sclerosis complications: what to use when first-line treatment fails\u2013a consensus of systemic sclerosis experts. Semin Arthritis Rheum. 2012;42(1):42\u201355.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"1517_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/00005382-200310000-00004","volume":"18","author":"H Arakawa","year":"2003","unstructured":"Arakawa H, Yamasaki M, Kurihara Y, Yamada H, Nakajima Y. Methotrexate-induced pulmonary injury: serial CT findings. J Thorac Imaging. 2003;18(4):231\u20136.","journal-title":"J Thorac Imaging"},{"issue":"5","key":"1517_CR15","first-page":"181","volume":"34 Suppl 100","author":"G Lepri","year":"2016","unstructured":"Lepri G, Avouac J, Airo P, Anguita Santos F, Bellando-Randone S, Blagojevic J, et al. Effects of rituximab in connective tissue disorders related interstitial lung disease. Clin Exp Rheumatol. 2016;34 Suppl 100(5):181\u20135.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"1517_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3899\/jrheum.120725","volume":"40","author":"A Lauretis De","year":"2013","unstructured":"De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol. 2013;40(4):435\u201346.","journal-title":"J Rheumatol"},{"issue":"10038","key":"1517_CR17","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387(10038):2630\u201340.","journal-title":"Lancet"},{"issue":"9","key":"1517_CR18","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","volume":"41","author":"VD Steen","year":"1998","unstructured":"Steen VD, Medsger Jr TA. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998;41(9):1613\u20139.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"1517_CR19","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.rmed.2010.03.018","volume":"104","author":"L Mouthon","year":"2010","unstructured":"Mouthon L, Berezne A, Guillevin L, Valeyre D. Therapeutic options for systemic sclerosis related interstitial lung diseases. Respir Med. 2010;104 Suppl 1:S59\u201369.","journal-title":"Respir Med"},{"issue":"8","key":"1517_CR20","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327\u20131339.","journal-title":"Ann Rheum Dis"},{"key":"1517_CR21","doi-asserted-by":"crossref","unstructured":"Rodnan GP, Medsger TA, Altman RD, D'Angelo WA, Fries JF, LeRoy EC, Kirsner AB, MacKensie AH, MacShane DJ, Myers AR, Sharp GC. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23(5):581-90.","DOI":"10.1002\/art.1780230510"},{"issue":"9","key":"1517_CR22","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/art.1780370903","volume":"37","author":"VD Steen","year":"1994","unstructured":"Steen VD, Conte C, Owens GR, Medsger Jr TA. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. 1994;37(9):1283\u20139.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1517_CR23","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/ard.2006.062901","volume":"66","author":"UA Walker","year":"2007","unstructured":"Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis. 2007;66(6):754\u201363.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1517_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1136\/ard.62.2.146","volume":"62","author":"C Morgan","year":"2003","unstructured":"Morgan C, Knight C, Lunt M, Black CM, Silman AJ. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis. 2003;62(2):146\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"2 Suppl 76","key":"1517_CR25","first-page":"157","volume":"31","author":"M Iudici","year":"2013","unstructured":"Iudici M, van der Goes MC, Valentini G, Bijlsma JW. Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review. Clin Exp Rheumatol. 2013;31(2 Suppl 76):157\u201365.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"1517_CR26","doi-asserted-by":"publisher","first-page":"R124","DOI":"10.1186\/ar2534","volume":"10","author":"C Nannini","year":"2008","unstructured":"Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther. 2008;10(5):R124.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"1517_CR27","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1136\/annrheumdis-2011-200389","volume":"71","author":"MO Becker","year":"2012","unstructured":"Becker MO, Schohe A, Weinert K, Huscher D, Schneider U, Burmester GR, et al. Responders to cyclophosphamide: results of a single-centre analysis among systemic sclerosis patients. Ann Rheum Dis. 2012;71(12):2061\u20132.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1517_CR28","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/rheumatology\/kei211","volume":"45","author":"SN Liossis","year":"2006","unstructured":"Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford). 2006;45(8):1005\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"1517_CR29","doi-asserted-by":"publisher","first-page":"143637","DOI":"10.1155\/2012\/143637","volume":"2012","author":"A Tzouvelekis","year":"2012","unstructured":"Tzouvelekis A, Galanopoulos N, Bouros E, Kolios G, Zacharis G, Ntolios P, et al. Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med. 2012;2012:143637.","journal-title":"Pulm Med"},{"issue":"4","key":"1517_CR30","first-page":"613","volume":"25","author":"C Paone","year":"2007","unstructured":"Paone C, Chiarolanza I, Cuomo G, Ruocco L, Vettori S, Menegozzo M, et al. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol. 2007;25(4):613\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"1517_CR31","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","volume":"35","author":"FH Hoogen van den","year":"1996","unstructured":"van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24\u00a0week randomized double-blind trial, followed by a 24\u00a0week observational trial. Br J Rheumatol. 1996;35(4):364\u201372.","journal-title":"Br J Rheumatol"},{"issue":"2","key":"1517_CR32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.1365-4632.2007.02887.x","volume":"46","author":"M Krishna Sumanth","year":"2007","unstructured":"Krishna Sumanth M, Sharma VK, Khaitan BK, Kapoor A, Tejasvi T. Evaluation of oral methotrexate in the treatment of systemic sclerosis. Int J Dermatol. 2007;46(2):218\u201323.","journal-title":"Int J Dermatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1517-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:59:47Z","timestamp":1548809987000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1517-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,30]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1517"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1517-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,30]]},"assertion":[{"value":"27 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prior to inclusion into the database each patient gave informed consent. Ethics approval was obtained from local ethics committees prior to start of the evaluation. Local ethics committees are represented by the locations listed after each author\u2019s name and after each co-worker\u2019s name as provided in Additional file .","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"17"}}